Conversation with The Cancer Letter Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.” March 13, 2026Vol.52 No.10By Paul Goldberg
Conversation with The Cancer Letter GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”Mainstream epidemiologists beg to differ March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center February 06, 2026Vol.52 No.05By Paul Goldberg
Conversation with The Cancer Letter John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC December 12, 2025Vol.51 No.45By Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Anthony Letai pledges to ensure stability for extramural and intramural cancer science December 05, 2025Vol.51 No.44By Paul Goldberg
Conversation with The Cancer Letter Shane Jacobson talks about his to-do list for ACSBoost research, forge closer ties with cancer centers, launch an all-out campaign for resources November 21, 2025Vol.51 No.43
Conversation with The Cancer LetterRegulatory News Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director November 14, 2025Vol.51 No.42By Paul Goldberg
Conversation with The Cancer LetterFreePodcast Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSUBrian Druker returns to executive role as president of the new Knight Cancer Group August 14, 2025Vol.51 No.32By Paul Goldberg and Sara Willa Ernst
Conversation with The Cancer Letter Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out July 25, 2025Vol.51 No.29By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg
